HERTHENA-Breast03: A phase 2, randomized, open-label study evaluating neoadjuvant patritumab deruxtecan + pembrolizumab before or after pembrolizumab + chemotherapy for early-stage TNBC or HR-low+/HER2− breast cancer.

Authors: Joyce O'Shaughnessy, Julie Marie Collins, Lili Yao, Karen L. Smith, Jaime A. Mejia, Michael A. Danso

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.tps629

Source: Full article

TPS629